Search

Summary The branchiomeric skeletal muscles co-evolved with new chambers of the heart to enable predatory feeding in chordates. These co-evolved tissues develop from a common population in anterior splanchnic mesoderm, referred to as cardiopharyngeal mesoderm (CPM). The regulation and development of CPM are poorly understood. We describe an embryonic stem cell-based system in which MESP1 drives a PDGFRA+ population with dual cardiac and skeletal muscle differentiation potential, and gene expression resembling CPM. Using this system, we investigate the regulation of these bipotent progenitors, and find that cardiac specification is governed by an antagonistic TGFβ-BMP axis, while skeletal muscle specification is enhanced by Rho kinase inhibition. We define transcriptional signatures of the first committed CPM-derived cardiac and skeletal myogenic progenitors, and discover surface markers to distinguish cardiac (PODXL+) from the skeletal muscle (CDH4+) CPM derivatives. These tools open an accessible window on this developmentally and evolutionarily important population., Graphical Abstract, Highlights • MESP1 induces bipotent PDGFRA+ cardiac/skeletal myogenic progenitors • MESP1+ PDGFRA+ cells functionally resemble cardiopharyngeal mesoderm (CPM) • TGFβ-BMP and Rho kinase signaling regulate CPM lineage choice • PODXL and CDH4 mark early cardiac and skeletal myogenic-committed progenitors, In this article, Kyba and colleagues demonstrate that a bipotent PDGFRA+ cardiac/skeletal myogenic progenitor population functionally resembling cardiopharyngeal mesoderm (CPM) can be generated from ES cells differentiated in vitro. They find that TGFβ-BMP and Rho kinase signaling regulate CPM differentiation, and identify PODXL and CDH4 as surface markers for the earliest cardiac and skeletal myogenic-committed progenitors, respectively.

Mesenchymal stem cells (MSCs) are multipotent adult stem cells found in a variety of tissues, including bone marrow, adipose, and umbilical cord. Although MSCs have the ability to differentiate into a variety of cell types useful for regenerative medicine, their ability to modulate the immune system has been at the forefront in the clinic. The mechanisms by which MSCs affect the immune system are not fully understood. This makes it difficult to design specific quality control measures for MSCs used for cell therapy as well as to understand what parameters are the most critical for their immunomodulatory abilities. This specific testing is important to determine batch-to-batch variability and to better forecast patient-to-patient efficacy. In this study, we demonstrate a workflow to investigate the effects of MSCs on immune cell subset populations. Human MSCs were co-cultured with human T cell subtypes (Th1, Th2, Th17, and Treg) that have been differentiated utilizing CellXVivo™ Differentiation Kits. Co-culture supernates are then analyzed via Proteome Profiler™ Antibody Arrays to screen for changes in cytokine levels, relative to MSCs cultured in the absence of T-cells. Analytes discovered to change in the screening arrays are then quantitated using Luminex® Assays. We hypothesize that these tools and techniques will allow for a better understanding of the mechanisms contributing to MSC immunomodulation and provide methods for routine quality control testing of MSC populations prior to clinical use.

Epithelial to mesenchymal transition (EMT) is essential for proper morphogenesis during development. Misregulation of this process has been implicated as a key event in fibrosis and the progression of carcinomas to a metastatic state. Understanding the processes that underlie EMT is imperative for the early diagnosis and clinical control of these disease states. Reliable induction of EMT in vitro is a useful tool for drug discovery as well as to identify common gene expression signatures for diagnostic purposes. Here we demonstrate a straightforward method for the induction of EMT in a variety of cell types. Methods for the analysis of cells pre- and post-EMT induction by immunocytochemistry are also included. Additionally, we demonstrate the effectiveness of this method through antibody-based array analysis and migration/invasion assays.